Advertisement
New Zealand markets open in 8 hours 46 minutes
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5923
    -0.0014 (-0.24%)
     
  • NZD/EUR

    0.5543
    -0.0003 (-0.06%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.81
    0.00 (0.00%)
     
  • GOLD

    2,337.70
    -0.70 (-0.03%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,067.13
    +26.75 (+0.33%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    17,902.67
    -186.03 (-1.03%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • NZD/JPY

    92.0490
    -0.0660 (-0.07%)
     

Analyst Recommendations for Herbalife before 4Q17

Analyst Recommendations for Herbalife before 4Q17

Of the analysts covering Herbalife (HLF) stock, 50% of them are recommending a “buy,” and 50% are recommending a “hold.” Herbalife’s sales and profitability were subdued in the first three quarters of 2017. Herbalife’s financials are expected to remain challenged in the near term, given the weakness in its key regions. Currently, analysts have a price target of $86.80 per share for Herbalife stock, which represents an upside of 3.5% compared to its closing price of $83.88 on February 15, 2018.